TibaRay

What TibaRay does

TibaRay is a private medical technology company founded in 2014 and headquartered in Fremont, California, that is developing next-generation linear accelerator systems for cancer radiotherapy. Its flagship product is the Galactica platform, a novel X-band linear accelerator employing distributed RF coupling and genetically optimized cell geometry, representing the first fundamentally new class of medical linear accelerator in nearly 70 years. This architecture enables FLASH radiotherapy - ultra-high dose-rate radiation delivery in fractions of a second rather than minutes - which can reduce collateral tissue damage by 20-30% and limit tumor motion sensitivity. The company also offers novel high-power RF components (isolators, circulators) for licensing, and applies its compact linac technology to adjacent markets including non-destructive testing for infrastructure inspection and high-speed cargo scanning for border security.

TibaRay operates a vertically integrated 24,000 sq ft manufacturing facility in Fremont with in-house CNC machining, hydrogen furnace, and radiation-safe testing infrastructure. Its business model is anchored on capital equipment sales of Galactica systems at a target price point of approximately $5 million per unit, in line with conventional linacs, supplemented by technology licensing of RF components. Go-to-market combines direct enterprise sales (first clinical installation planned at Mayo Clinic in 2026) with an OEM/embedded distribution partnership with Leo Cancer Care, whose Grace photon therapy platform will integrate Galactica linac technology with upright patient positioning. A strategic investment from Malaysia's IHH Healthcare provides a channel into Asian hospital networks, while an equity crowdfunding campaign via WeFunder broadens retail investor reach. The company is also pursuing government/defense opportunities in portable imaging systems.

The company is venture-backed with disclosed co-founders from Stanford and SLAC (Bill Loo, Sami Tantawi, Peter Maxim, Rebecca Fahrig) and CEO Thinh Tran. It is pre-commercial, with the first Galactica systems entering manufacturing in mid-2026 and initial clinical installations expected later that year. Peer-reviewed validation in Medical Physics, Radiotherapy and Oncology, and Physical Review Accelerators and Beams supports the underlying science, and the addressable medical linear particle accelerator market is projected at $3.44 billion by 2030.

Name

TibaRay

Legal name

TibaRay, Inc.

Website

https://tibaray.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

TibaRay is a Fremont, California-based medical technology company developing the Galactica linear accelerator platform, which enables FLASH radiotherapy for cancer treatment and serves oncology centers, with adjacent applications in industrial imaging and security scanning.

Ownership category

akta.pro rank

Product category

Medical Linear Accelerators

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)

akta.pro primary industry

Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

• Linear accelerator systems
• FLASH radiotherapy technology
• Medical particle accelerators
• RF component manufacturing
• Cancer treatment equipment

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of Galactica linear accelerator systems to healthcare providers and cancer treatment centers. First clinical installation planned at Mayo Clinic.
2. Technology Licensing: Licensing of novel RF components and accelerator technology to third-party manufacturers.
3. Industrial Imaging Systems: Sale of compact linac systems for non-destructive testing and infrastructure inspection.
4. Security Imaging Systems: High-speed cargo inspection and border security scanning systems.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

TibaRay designs, manufactures, and sells the Galactica linear accelerator platform, a next-generation X-band medical linac based on distributed RF coupling and genetically optimized cell geometry. The platform enables FLASH radiotherapy delivery in fractions of a second, upright patient positioning, and is targeted at major cancer treatment centers, beginning with the first clinical installation at Mayo Clinic. The company also produces novel high-power RF components and applies its compact linac technology to non-destructive testing and border security imaging applications.

Product overview

TibaRay offers a unified core technology platform centered on its proprietary Galactica™ linear accelerator, representing the first fundamentally new class of medical linear accelerator in nearly 70 years. The platform enables next-generation radiotherapy including FLASH therapy and eXactFLASH™. The company also manufactures novel RF components (high-power isolators and circulators) and applies its accelerator technology across three markets: healthcare (radiotherapy and proton therapy via Phaser), non-destructive testing for infrastructure, and border security cargo scanning.

Differentiator

Problem solved

Functional benefit

Brands

• Galactica™: The flagship linear accelerator platform designed as the first fundamentally new class of medical linear accelerator in nearly 70 years, enabling FLASH radiotherapy treatment with patients sitting or standing.
• eXactFLASH™

Products and services

• Galactica Linear Accelerator Platform TibaRay's flagship linear accelerator platform representing the first fundamentally new class of medical linear accelerator in nearly 70 years. Generates high-energy X-rays for cancer treatment in a smaller, more efficient platform that enables FLASH radiotherapy with patients treated while sitting or standing rather than lying down. Targeted at major cancer treatment centers, hospital oncology departments, and radiation therapy providers.
• Phaser Proton Therapy System Proton therapy machine capable of treating patients up to 400 times faster than conventional radiotherapy. Part of TibaRay's radiotherapy technology portfolio designed for cancer treatment centers and proton therapy facilities.
• High-Power RF Isolator Novel high-power RF isolator design delivering significantly improved performance, enhanced reliability, scalability, and more cost-efficient manufacturing. Can be customized to meet specific customer requirements for accelerator system builders and integrators.
• High Power Compact Circulator RF component for power distribution and signal routing in accelerator systems. Sourced from TibaRay's proprietary high-power RF component portfolio for accelerator manufacturers and integrators.
• Non-Destructive Testing Imaging Systems Portable, field-deployable compact linac systems for advanced non-destructive testing and imaging of infrastructure without disassembly or destructive testing. Features high-resolution structural imaging and faster inspection cycles for infrastructure companies, manufacturing facilities, and safety inspectors.
• Border Security Cargo Scanning Systems High-speed cargo inspection systems enabling continuous imaging workflows for modern security demands. Features real-time scanning at operational speeds, high throughput inspection capability, and improved detection accuracy for government agencies and border security organizations.

Quantifiable outcome

• FLASH therapy delivers radiotherapy in a fraction of a second, not minutes
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Leo Cancer CarecoreTechnology or Integration · 12 July 2026Strategic integration partnership for Galactica linac technology into Leo Cancer Care's radiotherapy platform. Systems to be integrated into Leo Cancer Care's Grace photon therapy platform and upright patient positioning system. First clinical installation planned at Mayo Clinic. Partnership validates clinical-market pull and partner confidence.
• Leo Cancer CarecoreTechnology or Integration · 1 June 2024June 2024 partnership to develop upright linear accelerator combining TibaRay's accelerator technology with Leo Cancer Care's patient positioning and imaging system.
• Stanford MedicinecoreStrategic or Co-development PartnerStanford Medicine treated its first patient in new upright proton therapy facility, validating the Leo Cancer Care upright patient positioning platform that will integrate TibaRay's Galactica linac technology. Stanford research foundation enables technology validation at world-renowned cancer center.
• Government CustomersminorOthersPortable high-performance imaging development for Government customers in security and defense applications.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Accuray: Accuray manufactures the CyberKnife and TomoTherapy radiotherapy systems used in cancer treatment centers worldwide. It is a direct peer to TibaRay in radiation therapy delivery equipment.
• IBA (Ion Beam Applications): IBA is one of the world's largest proton therapy and particle accelerator equipment makers for cancer care. Its ProteusOne and ProteusPLUS systems compete with TibaRay's broader particle-beam radiotherapy strategy.
• Elekta: Elekta is a global leader in radiation therapy and radiosurgery hardware (Elekta Versa HD, Elekta Unity MR-Linac). It directly competes with TibaRay in the medical linac / radiation oncology equipment market.
• Mevion Medical Systems: Mevion is a proton therapy equipment maker focused on compact single-room proton therapy systems. TibaRay's Phaser ultra-fast proton platform targets the same oncology customer with a complementary faster-delivery approach.
• ViewRay: ViewRay develops the MRIdian MR-guided radiation therapy system, combining real-time MRI with linear accelerators. It is a direct competitor in next-generation image-guided radiotherapy hardware.
• Varian Medical Systems (a Siemens Healthineers company): Varian (now part of Siemens Healthineers) is the largest global manufacturer of medical linear accelerators and radiotherapy systems, including the TrueBeam and Halcyon platforms. TibaRay competes in the same medical linac category with a novel X-band FLASH-capable architecture.

Emerging players

• RefleXion Medical: RefleXion developed the biology-guided radiotherapy (BgRT) platform, an emerging PET-linac hybrid system. It is a smaller, early-commercial competitor to TibaRay in next-generation radiotherapy delivery.
• Zap Surgical: Zap Surgical markets the Zap-X self-shielded radiosurgery system, a non-invasive platform for brain and body SRS. It is an emerging linac-based radiosurgery competitor in TibaRay's broader radiotherapy equipment category.
• Leo Cancer Care: Leo Cancer Care is the strategic integration partner commercializing TibaRay's Galactica within the upright Grace photon therapy platform. While partner-dependent, it competes in upright patient positioning and photon therapy system integration.

Others

• C-RAD: C-RAD provides patient positioning, surface guidance, and motion management systems for radiotherapy, complementing TibaRay's accelerator hardware with positioning technology similar to what Leo Cancer Care supplies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/tibarayinc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TibaRay